Biogen Inc. (NASDAQ:BIIB) Q2 2024 Earnings Call Transcript August 1, 2024 8:30 AM ET

Company Participants

Chuck Triano - Head of IR
Chris Viehbacher - President and CEO
Alisha Alaimo - Head and President of North America
Priya Singhal - Head of Development
Travis Murdoch - Head of HI-Bio
Mike McDonnell - CFO

Conference Call Participants

Salveen Richter - Goldman Sachs
Evan Seigerman - BMO Capital Markets
Michael DiFiore - Evercore ISI
Nicole Gabreski - Piper Sandler
Paul Matteis - Stifel
Michael Yee - Jefferies
Eric Schmidt - Cantor Fitzgerald

Operator

Good morning. My name is Anna and I will be your conference operator today. At this time, I would like to welcome everyone to the Biogen Second Quarter 2024 Earnings Call and Business Update. All lines have been placed on mute to prevent any background noise. After the speaker's remarks, there will be a question-and-answer session. [Operator Instructions] Today's conference is being recorded. Thank you.

I would now like to turn the conference over to Mr. Chuck Triano, Head of Investor Relations. Mr. Triano, you may begin your conference.

Chuck Triano

Thank you. Good morning, good afternoon, and welcome to Biogen's second quarter 2024 earnings call.

During this call, we'll make forward-looking statements which involve risks and uncertainties that may cause actual results to differ materially from those in our forward-looking statements. We provide a comprehensive list of risk factors in our SEC filings, which I encourage you to review. Our earnings release and other documents related to our results, as well as the reconciliation between GAAP and non-GAAP results discussed on the call, can be found in the Investors section at biogen.com. We have also posted the slides on our website that will be used during this call.

On today's call, I'm joined by our President and Chief Executive Officer, Chris Viehbacher; our Head and President of North America, Alisha Alaimo; Dr. Priya Singhal, Head of Development; Mike McDonnell, Chief Financial Officer, and we'll be introducing Dr. Travis Murdoch from HI-Bio on the call. We'll make some opening comments and then we'll move to the Q&A session. And to allow us to get through as many questions as possible, we ask that you limit yourself to one question.

With that, I'll now turn the call over to Chris.

Chris Viehbacher

Thanks, Chuck. We got a lot to cover this morning, but first, in addition to our regular team of Priya, Alisha, and Mike, I'd like to welcome a new member to our team, Dr. Travis Murdoch. Travis is a physician who trained as a gastroenterologist and then studied immunology as a Rhodes Scholar at Oxford. Following a career at McKinsey, Third Rock, and Softbank, he became the founder and CEO of HI-Bio. I'm pleased to welcome Travis and the HI-Bio team to Biogen. We now have, again, a presence on the West Coast. And the HI-Bio team, working in collaboration with their Biogen colleagues on the East Coast, will drive forward the development of felzartamab.